Zydus Lifesciences gets USFDA nod for generic medication

Zydus Lifesciences has received approval from the USFDA to market Amantadine extended-release capsules (68.5 mg) and tentative approval for Gocovri (137 mg) capsules for treating Parkinson's disease. The drug will be produced at the company's Ahmedabad facility, making Zydus eligible for 180 days of exclusivity for Amantadine capsules.